Manager TitleAgeSince
Chief Operating Officer - 13/11/2022
Director TitleAgeSince
Director/Board Member 61 15/08/2005
Chairman 67 18/09/2014
Director/Board Member 56 04/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-4.12% - - 1.28M
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
+0.50%+7.13%+33.27%+16.01% 26.34B
-3.21%-7.27%-17.10%+356.10% 26.21B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
-1.26%-7.81%+156.15%+320.43% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.24B
Average -0.58%+1.65%+35.97%+207.33% 30.54B
Weighted average by Cap. -0.47%+1.44%+35.38%+147.72%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!